Home Corporate Overview Human Medicine Veterinary Medicine Publications News Investor Relations Careers Contact Relations Investisseurs Accueil Select year : 2017 2016 2015 2014 2013 2012 2011 2010 AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment 14/09/2017 - AB Science intends to initiate a confirmatory study in patients with smouldering or indolent systemic severe mastocytosis to confirm the results from this first pivotal study First half of 2017 results 31/08/2017 - AB Science reports its revenues for the first half of 2017 and provides an update on its activites AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients with pain until 2033 12/07/2017 - Recruitment target before possible resampling of masitinib confirmatory study in pancreatic cancer has been reached AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association (EHA) 22/06/2017 - Abstract selected for presentation by the EHA Scientific Program Committee AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) at the European Network for the Cure of ALS (ENCALS) annual meeting 18/05/2017 - Study was a success showing masitinib to be safe and effective treatment in ALS AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings 17/05/2017 - AB Science will ask for a re-examination with the opinion of Scientific Advisory Group (SAG) to evaluate the benefit-risk balance Summary of the conference call held on May 12, 2017 15/05/2017 - AB Science provides a summary of the questions and answers of both conference calls held on May 12, 2017 following ANSM decision requesting suspension of clinical studies in France AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice (GCP) standards 12/05/2017 - ANSM accepted the principle of restarting the clinical studies on the basis of the findings of an independent audit Annual financial results as of December 31, 2016 01/05/2017 - AB Science reports on its annual financials as of 31 December 2016 and provides an update on its activities AB Science announces the success of a private placement 31/03/2017 - EUR 19.0 million raised through a private placement of 1,241,831 new ordinary shares AB Science announces that masitinib in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years 29/03/2017 - The study has completed patient recruitment AB Science announces the success of a private placement 27/03/2017 - EUR 15.0 million raised through a private placement of 982,962 new ordinary shares Masitinib in Amyotrophic Lateral Sclerosis (ALS) 22/03/2017 - Presentation of the web conference held on Marc 20, 2017 AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS) 20/03/2017 - Primary analysis is a success and confirms interim analysis AB Science announces that Frontiers in Aging Neuroscience publishes a comprehensive review on the future potential of masitinib in amyotrophic lateral sclerosis (ALS) 07/03/2017 - This article reviews over 50 advanced-stage clinical trials in 24 candidate drugs conducted over the last 20 years AB Science announces completion of patient recruitment for phase 3 study in severe persistent asthma 06/03/2017 - The phase 3 study in severe persistent asthma uncontrolled by oral corticosteroids has completed patient recruitment. Final results will be available at the end of 2017. A new phase 3 study has been initiated in asthma uncontrolled by high-dose inhaled corticosteroids and with elevated eosinophil level. AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis 09/01/2017 - Masitinib is the first drug to demonstrate efficacy in a phase 3 study of adult patients with severe indolent systemic mastocytosis New preclinical data demonstrate that masitinib has an unexpected protective effect on muscles and nerves in Amyotrophic Lateral Sclerosis 03/01/2017 - These new data have been presented at the 27th International Symposium on ALS/MND in December 2016 in Dublin, Ireland. © COPYRIGHT AB SCIENCES. ALL RIGHTS RESERVED. I MASIVET® I KINAVET® I LEGAL NOTICE I DESIGN : AGENCE K2